A peer-reviewed mouse and cell study found that an antibody targeting extracellular vimentin reduced signs of intestinal inflammation and fibrosis-related changes. Experiments with human-derived colon cells also examined the proposed pathway. This is preclinical evidence from a single study; efficacy, dosage and long-term safety in people with inflammatory bowel disease remain unestablished.
Science··Morning
An extracellular protein becomes an experimental target
An antibody targeting vimentin outside cells eased signs of intestinal inflammation in a peer-reviewed mouse and cell study. Vimentin is a structural protein inside cells, while its extracellular form also participates in inflammatory processes. Researchers used dextran sodium sulfate to induce colitis, or inflammation of the colon, in mice. Antibody treatment was associated with less weight loss and less shortening of the colon. These findings concern one experimental model, with no clinical treatment trial in people.[1]
Tissue markers fall alongside the symptoms
Tissue analyses found reductions in inflammation and fibrosis-related markers. Fibrosis is excessive connective-tissue accumulation that can stiffen tissue. The experiments also assessed inflammatory cytokines and markers associated with necroptosis, a regulated form of cell death linked to inflammation. This range of measurements connected the antibody intervention with changes in intestinal injury and inflammatory responses. It does not determine how a chronic human disease responds over a longer period or establish comparative efficacy against existing medicines.[1]
Colon-cell experiments examine the same pathway
In human-derived CCD18CO colon cells, stimulation with TGF-beta was used to examine fibrosis-related responses. Extracellular vimentin enhanced the associated factors in this setting. The antibody countered that response. Cell cultures offer support for the proposed mechanism within a controlled setting. They leave human dosage, long-term safety and treatment efficacy unresolved. The dose-response relationship was not comprehensively tested, and both the mouse model and cultured cells represent only part of the complexity of inflammatory bowel disease.[1]
